Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• Chemically the active drug (semaglutide) can be the same, but “compounded semaglutide” and brand-name Wegovy are very different in regulation, testing, formulation, delivery, and proven safety/effectiveness. Wegovy is FDA‑approved for chronic weight management; compounded products are not.

Key differences

1. Regulatory approval and evidence

• Wegovy (Novo Nordisk) — FDA approved after large randomized clinical trials showing efficacy and safety for weight management at the labeled dosing. Label, warnings and manufacturing are regulated.
• Compounded semaglutide — made on a prescription-by-prescription basis by a compounding pharmacy or clinic. Not FDA‑approved as a product, so it has not gone through the same clinical trials or regulatory review.

1. Manufacturing quality and testing

• Wegovy is made under pharmaceutical good manufacturing practice (GMP) with batch testing for identity, purity, potency and sterility.
• Compounded products may vary widely by pharmacy. Some compounding pharmacies follow stringent standards and testing; others may not. Risks include variable potency, contamination, incorrect concentrations, and unknown stability.

1. Formulation and delivery device

• Wegovy is supplied in prefilled injection pens and specific dose-escalation packages designed to reduce dosing errors.
• Compounded semaglutide is often supplied as vials or in syringes prepared locally. Excipients, diluents, and stability in a compounded formulation may differ, which can affect absorption and shelf life. Using vials/syringes increases the chance of dosing or injection errors.

1. Safety labeling and warnings

• Wegovy’s label includes boxed warnings and specific guidance (e.g., risk of medullary thyroid carcinoma in rodents, pancreatitis warnings, pregnancy considerations, etc.) and the manufacturer tracks adverse events.
• Compounded products lack standardized labeling and post‑marketing surveillance; the same theoretical risks exist, but there’s less systematic data.

1. Legal/regulatory considerations

• FDA and state boards allow compounding in certain circumstances but generally discourage compounding of an FDA‑approved drug when an approved product is available. The regulatory environment is more limited for compounded biologic/peptide products.
• Insurance coverage: Wegovy may be covered under certain plans (or patient-assistance programs). Compounded semaglutide is usually paid out of pocket and may be cheaper, but that comes with tradeoffs.

1. Cost and access

• Wegovy is expensive for many people. Compounded versions are marketed as lower-cost alternatives — that’s often true, but you’re trading lower cost for less regulatory oversight and potentially greater risk.

What “equivalent” really means

• If a reputable compounding pharmacy uses high‑quality API and validated sterile compounding processes, the active ingredient can be the same, but because the compounded product lacks the manufacturer’s stability testing, device engineering and clinical trial data, you cannot assume the same safety, potency consistency, or clinical outcomes.

Practical recommendations

• Prefer FDA‑approved Wegovy (Novo Nordisk) when possible for proven dosing, safety data, and a regulated manufacturing process.
• If you consider compounded semaglutide because of cost or access:
  • Use a highly reputable compounding pharmacy — one that is PCAB‑accredited and follows USP standards (USP <797>/<800>). Ask for proof of accreditation.
  • Ask the pharmacy for a Certificate of Analysis (COA) for the API, sterility/endotoxin testing, batch records, and documented shelf life/storage conditions.
  • Make sure your prescribing clinician documents the rationale and monitors you closely for side effects (pancreatitis symptoms, thyroid issues, gallbladder problems, severe GI side effects, etc.).
  • Avoid using products from clinics or suppliers that won’t provide testing data or that mix or repackage in-house without sterility testing.

Alternatives to consider

• Ozempic (Novo Nordisk) — same active (semaglutide) but labeled for type 2 diabetes; sometimes used off‑label by prescribers for weight loss at different doses.
• Rybelsus (oral semaglutide) — oral form of semaglutide (different administration).
• Tirzepatide products: Mounjaro (Eli Lilly, diabetes) and Zepbound (Eli Lilly, weight management) — different drug (GIP/GLP‑1 dual agonist) with strong weight‑loss data; may be alternatives depending on your situation.

Bottom line Wegovy gives you an FDA‑approved, thoroughly tested formulation and delivery system with known dosing, labeling and post‑marketing safety tracking. Compounded semaglutide can be cheaper and sometimes chemically identical, but it carries higher uncertainty about potency, purity, sterility, stability and documented clinical performance. If you’re considering a compounded product, insist on a PCAB‑accredited pharmacy and specific testing documentation, and discuss risks and monitoring with your clinician. If you’d like, tell me whether cost, insurance, or access is the main issue and I can suggest practical next steps (patient assistance programs, manufacturer savings, or how to vet compounding pharmacies).